These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 37519275)
1. Single BRAFV600E mutation is not associated with aggressive biological behavior in adolescent and pediatric papillary thyroid carcinoma. Zhou B; Lu X; Hei H; Zhang S; Li Y; Fang J; Qin J; Ge H Cancer Cytopathol; 2023 Nov; 131(11):716-723. PubMed ID: 37519275 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors. Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049 [TBL] [Abstract][Full Text] [Related]
3. The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas. Li Y; Wang Y; Li L; Qiu X Sci Rep; 2022 Jul; 12(1):12674. PubMed ID: 35879379 [TBL] [Abstract][Full Text] [Related]
4. More aggressive biological behavior in pediatric than in adult papillary thyroid carcinoma. Zhou B; Hei H; Fang J; Qin J; Ge H Asian J Surg; 2024 Jan; 47(1):443-449. PubMed ID: 37805323 [TBL] [Abstract][Full Text] [Related]
5. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma. Kim YS; Kim JS; Bae JS; Park WC World J Surg Oncol; 2013 May; 11():99. PubMed ID: 23687957 [TBL] [Abstract][Full Text] [Related]
6. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Li F; Chen G; Sheng C; Gusdon AM; Huang Y; Lv Z; Xu H; Xing M; Qu S Endocr Relat Cancer; 2015 Apr; 22(2):159-68. PubMed ID: 25593071 [TBL] [Abstract][Full Text] [Related]
7. BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer. Campennì A; Ruggeri RM; Giuffrè G; Siracusa M; Alibrandi A; Cardile D; La Torre F; Lanzafame H; Giacoppo G; Ieni A; Trimarchi F; Tuccari G; Baldari S Nucl Med Commun; 2021 Jun; 42(6):611-618. PubMed ID: 33625185 [TBL] [Abstract][Full Text] [Related]
8. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Virk RK; Van Dyke AL; Finkelstein A; Prasad A; Gibson J; Hui P; Theoharis CG; Carling T; Roman SA; Sosa JA; Udelsman R; Prasad ML Mod Pathol; 2013 Jan; 26(1):62-70. PubMed ID: 22918165 [TBL] [Abstract][Full Text] [Related]
10. Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma. Sezer A; Celik M; Yilmaz Bulbul B; Can N; Tastekin E; Ayturk S; Ustun F; Guldiken S; Sut N Bosn J Basic Med Sci; 2017 May; 17(2):144-151. PubMed ID: 28284178 [TBL] [Abstract][Full Text] [Related]
11. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study. Park VY; Kim EK; Lee HS; Moon HJ; Yoon JH; Kwak JY Medicine (Baltimore); 2015 Jul; 94(28):e1149. PubMed ID: 26181555 [TBL] [Abstract][Full Text] [Related]
12. BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China. Zheng X; Xia T; Lin L; Gao S; Lee Y; Yu Y; Wei S; Gao M World J Surg Oncol; 2012 Jun; 10():104. PubMed ID: 22681706 [TBL] [Abstract][Full Text] [Related]
13. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278 [TBL] [Abstract][Full Text] [Related]
14. Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis. Kim WW; Ha TK; Bae SK J Otolaryngol Head Neck Surg; 2018 Jan; 47(1):4. PubMed ID: 29316976 [TBL] [Abstract][Full Text] [Related]
15. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer. Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729 [TBL] [Abstract][Full Text] [Related]
16. The synergic effect of BRAF Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763 [TBL] [Abstract][Full Text] [Related]
17. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. Sancisi V; Nicoli D; Ragazzi M; Piana S; Ciarrocchi A J Clin Endocrinol Metab; 2012 Sep; 97(9):E1745-9. PubMed ID: 22740704 [TBL] [Abstract][Full Text] [Related]
18. Effect and Interactions of BRAF on Lymph Node Metastasis in Papillary Thyroid Carcinoma With Hashimoto Thyroiditis. Li P; Liu Y; Wei T; Wang X; Zhu J; Yang R; Gong Y; Zhao W J Clin Endocrinol Metab; 2024 Mar; 109(4):944-954. PubMed ID: 37967234 [TBL] [Abstract][Full Text] [Related]
19. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011 [TBL] [Abstract][Full Text] [Related]
20. [Correlation between BRAF Zhou B; Hei H; Li YQ; Zhang DY; Wang DQ; Qin JW Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(14):1060-1063. PubMed ID: 37032157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]